drugset
drugset / Trial / NCT02131688

Phase I Study of Mitoxantrone Hydrochloride Liposome Injection

NCT02131688 ↗

Phase 1 Unknown 30 enrolled CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Parallel-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the maximum tolerated dose,the safety and effectiveness of Mitoxantrone Hydrochloride Liposome Injection.

Timeline

Start
2013-05
Primary completion
2015-08
Completion
2015-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Mitoxantrone Small molecule 18 mg/m2 —

Indications

lymphoma